摘要
目的探讨依达拉奉对急性心肌梗死(AMI)溶栓后再灌注损伤的影响。方法 72例AMI患者被随机分为治疗组(n=37)与对照组(n=35)。观察2组再灌注心律失常发生率,测定治疗后2 h、24 h磷酸肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(cTnI)。结果 2组治疗后24 h CK-MB2、h、24 h cTnI均有显著性差异。结论在常规抗心肌缺血治疗基础上加用依达拉奉,可明显减轻再灌注损伤,改善AMI患者的生存率及预后。
Objective To explore the effect of Edaravone on acute myocardial infarction （AMI） after thrombolytic reperfusion injury. Methods Seventy-two cases of AMI patients were randomly divided into, treatment group（ n = 37）and control group（ n = 35）. The incidence of reper- fusion arrhythmias, measured 2 houn3, 24 - hour of CK - MB and cardiac troponin I （cTnI） levels. Results After the treatment, there were significantly differences of 24 - hour of CK- MB, 2 hours and 24 - hour of cardiac troponin I （cTnI） levels between two groups. Conclusion The convention- al anti- ischemic therapy, in addition to edaravone, can significantly reduce reperfusion injury and improve survival and prognosis of patients with AMI.
出处
《实用临床医药杂志》
CAS
2011年第23期67-68,共2页
Journal of Clinical Medicine in Practice
关键词
依达拉奉
急性心肌梗死
再灌注损伤
Edaravolle
acute myocardial infarction
reperfusion injury
